You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRamipril
Accession NumberDB00178  (APRD00009)
TypeSmall Molecule
GroupsApproved
DescriptionRamipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril may be used in the treatment of hypertension, congestive heart failure, nephropathy, and to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events.
Structure
Thumb
Synonyms
(2S-(1(R*(r*)),2alpha,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid
Altace (tn)
Ramipril
Ramiprilum
Tritace
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ach-ramiprilcapsule5 mgoralAccord Healthcare IncNot applicableNot applicableCanada
Ach-ramiprilcapsule10 mgoralAccord Healthcare IncNot applicableNot applicableCanada
Ach-ramiprilcapsule1.25 mgoralAccord Healthcare IncNot applicableNot applicableCanada
Ach-ramiprilcapsule15 mgoralAccord Healthcare IncNot applicableNot applicableCanada
Ach-ramiprilcapsule2.5 mgoralAccord Healthcare IncNot applicableNot applicableCanada
Act Ramiprilcapsule2.5 mgoralActavis Pharma Company2007-10-02Not applicableCanada
Act Ramiprilcapsule5 mgoralActavis Pharma Company2007-10-02Not applicableCanada
Act Ramiprilcapsule10 mgoralActavis Pharma Company2007-10-02Not applicableCanada
Act Ramiprilcapsule1.25 mgoralActavis Pharma Company2007-10-02Not applicableCanada
Altacetablet2.5 mgoralValeant Canada Lp Valeant Canada S.E.C.Not applicableNot applicableCanada
Altacecapsule10 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2010-05-24Not applicableUs
Altacecapsule15 mgoralValeant Canada Lp/valeant Canada s.e.c.2006-08-14Not applicableCanada
Altacecapsule10 mg/1oralPfizer Laboratories Div Pfizer Inc1991-01-28Not applicableUs
Altacetablet1.25 mgoralValeant Canada Lp Valeant Canada S.E.C.Not applicableNot applicableCanada
Altacecapsule1.25 mg/1oralPfizer Laboratories Div Pfizer Inc1991-01-28Not applicableUs
Altacecapsule5 mgoralValeant Canada Lp Valeant Canada S.E.C.1997-04-21Not applicableCanada
Altacetablet5 mgoralValeant Canada Lp Valeant Canada S.E.C.Not applicableNot applicableCanada
Altacecapsule2.5 mg/1oralPfizer Laboratories Div Pfizer Inc1991-01-28Not applicableUs
Altacecapsule1.25 mgoralValeant Canada Lp Valeant Canada S.E.C.1997-05-28Not applicableCanada
Altacetablet10 mgoralValeant Canada Lp Valeant Canada S.E.C.Not applicableNot applicableCanada
Altacecapsule2.5 mgoralValeant Canada Lp/valeant Canada s.e.c.1997-04-21Not applicableCanada
Altacecapsule5 mg/1oralPfizer Laboratories Div Pfizer Inc1991-01-28Not applicableUs
Altacecapsule10 mgoralValeant Canada Lp Valeant Canada S.E.C.1997-03-24Not applicableCanada
Altace Cap 1.25mgcapsule1.25 mgoralHoechst Roussel Canada Inc.1993-12-311999-08-11Canada
Altace Cap 10mgcapsule10 mgoralHoechst Roussel Canada Inc.1993-12-311999-08-11Canada
Altace Cap 2.5mgcapsule2.5 mgoralHoechst Roussel Canada Inc.1993-12-311999-08-11Canada
Altace Cap 5mgcapsule5 mgoralHoechst Roussel Canada Inc.1993-12-311999-08-11Canada
Auro-ramiprilcapsule5 mgoralAuro Pharma Inc2012-09-13Not applicableCanada
Auro-ramiprilcapsule10 mgoralAuro Pharma Inc2012-09-13Not applicableCanada
Auro-ramiprilcapsule1.25 mgoralAuro Pharma Inc2012-09-13Not applicableCanada
Auro-ramiprilcapsule2.5 mgoralAuro Pharma Inc2012-09-13Not applicableCanada
Ava-ramipriltablet10 mgoralAvanstra Inc2011-09-192014-08-21Canada
Ava-ramipriltablet1.25 mgoralAvanstra Inc2011-09-192014-08-21Canada
Ava-ramipriltablet2.5 mgoralAvanstra Inc2011-09-192014-08-21Canada
Ava-ramipriltablet5 mgoralAvanstra Inc2011-09-192014-08-21Canada
Bio-ramiprilcapsule2.5 mgoralBiomed PharmaNot applicableNot applicableCanada
Bio-ramiprilcapsule5 mgoralBiomed PharmaNot applicableNot applicableCanada
Bio-ramiprilcapsule10 mgoralBiomed PharmaNot applicableNot applicableCanada
Dom-ramiprilcapsule10 mgoralDominion Pharmacal2010-06-01Not applicableCanada
Dom-ramiprilcapsule1.25 mgoralDominion Pharmacal2010-06-01Not applicableCanada
Dom-ramiprilcapsule2.5 mgoralDominion Pharmacal2010-06-01Not applicableCanada
Dom-ramiprilcapsule5 mgoralDominion Pharmacal2010-06-01Not applicableCanada
Ipg-ramiprilcapsule1.25 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-ramiprilcapsule15 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-ramiprilcapsule2.5 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-ramiprilcapsule5 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-ramiprilcapsule10 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-ramiprilcapsule10 mgoralJamp Pharma Corporation2010-03-10Not applicableCanada
Jamp-ramiprilcapsule1.25 mgoralJamp Pharma Corporation2010-03-10Not applicableCanada
Jamp-ramiprilcapsule2.5 mgoralJamp Pharma Corporation2010-03-10Not applicableCanada
Jamp-ramiprilcapsule15 mgoralJamp Pharma Corporation2015-09-08Not applicableCanada
Jamp-ramiprilcapsule5 mgoralJamp Pharma Corporation2010-03-10Not applicableCanada
Mar-ramiprilcapsule5.0 mgoralMarcan Pharmaceuticals Inc2015-01-09Not applicableCanada
Mar-ramiprilcapsule10.0 mgoralMarcan Pharmaceuticals Inc2015-01-09Not applicableCanada
Mar-ramiprilcapsule1.25 mgoralMarcan Pharmaceuticals Inc2015-06-17Not applicableCanada
Mar-ramiprilcapsule15.0 mgoralMarcan Pharmaceuticals Inc2014-09-10Not applicableCanada
Mar-ramiprilcapsule2.5 mgoralMarcan Pharmaceuticals Inc2015-01-09Not applicableCanada
Mint-ramiprilcapsule2.5 mgoralMint Pharmaceuticals Inc2014-03-17Not applicableCanada
Mint-ramiprilcapsule1.25 mgoralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mint-ramiprilcapsule5.0 mgoralMint Pharmaceuticals Inc2014-03-17Not applicableCanada
Mint-ramiprilcapsule10.0 mgoralMint Pharmaceuticals Inc2014-03-17Not applicableCanada
Mint-ramiprilcapsule15.0 mgoralMint Pharmaceuticals Inc2014-03-17Not applicableCanada
Mylan-ramiprilcapsule1.25 mgoralMylan Pharmaceuticals Ulc2008-07-02Not applicableCanada
Mylan-ramiprilcapsule2.5 mgoralMylan Pharmaceuticals Ulc2008-07-02Not applicableCanada
Mylan-ramiprilcapsule5.0 mgoralMylan Pharmaceuticals Ulc2008-07-02Not applicableCanada
Mylan-ramiprilcapsule10 mgoralMylan Pharmaceuticals Ulc2008-07-02Not applicableCanada
PMS-ramiprilcapsule10 mgoralPharmascience Inc2009-10-06Not applicableCanada
PMS-ramiprilcapsule15 mgoralPharmascience Inc2010-05-11Not applicableCanada
PMS-ramiprilcapsule2.5 mgoralPharmascience Inc2009-10-06Not applicableCanada
PMS-ramiprilcapsule1.25 mgoralPharmascience Inc2009-10-06Not applicableCanada
PMS-ramiprilcapsule5 mgoralPharmascience Inc2009-10-06Not applicableCanada
Priva-ramiprilcapsule2.5 mgoralPharmapar IncNot applicableNot applicableCanada
Priva-ramiprilcapsule5 mgoralPharmapar IncNot applicableNot applicableCanada
Priva-ramiprilcapsule10 mgoralPharmapar IncNot applicableNot applicableCanada
Pro-ramipril - 1.25capsule1.25 mgoralPro Doc Limitee2011-11-25Not applicableCanada
Pro-ramipril - 10capsule10 mgoralPro Doc Limitee2011-11-25Not applicableCanada
Pro-ramipril - 2.5capsule2.5 mgoralPro Doc Limitee2011-11-25Not applicableCanada
Pro-ramipril - 5capsule5 mgoralPro Doc Limitee2011-11-25Not applicableCanada
Ramacetablet1.25 mgoralSanofi Aventis Canada IncNot applicableNot applicableCanada
Ramacetablet2.5 mgoralSanofi Aventis Canada IncNot applicableNot applicableCanada
Ramacetablet5 mgoralSanofi Aventis Canada IncNot applicableNot applicableCanada
Ramacetablet10 mgoralSanofi Aventis Canada IncNot applicableNot applicableCanada
Ramiprilcapsule10 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Ramiprilcapsule5 mgoralSivem Pharmaceuticals Ulc2010-03-01Not applicableCanada
Ramiprilcapsule2.5 mgoralLaboratoire Riva Inc2008-03-14Not applicableCanada
Ramiprilcapsule1.25 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Ramiprilcapsule1.25 mgoralSivem Pharmaceuticals Ulc2010-03-01Not applicableCanada
Ramiprilcapsule2.5 mgoralSanis Health Inc2011-11-24Not applicableCanada
Ramiprilcapsule10 mgoralSivem Pharmaceuticals Ulc2010-03-01Not applicableCanada
Ramiprilcapsule5 mgoralLaboratoire Riva Inc2008-03-14Not applicableCanada
Ramiprilcapsule2.5 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Ramiprilcapsule5 mgoralSanis Health Inc2011-11-24Not applicableCanada
Ramiprilcapsule10 mgoralLaboratoire Riva Inc2008-03-14Not applicableCanada
Ramiprilcapsule5 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Ramiprilcapsule10 mgoralSanis Health Inc2011-11-24Not applicableCanada
Ramiprilcapsule2.5 mgoralSivem Pharmaceuticals Ulc2010-03-01Not applicableCanada
Ramiprilcapsule1.25 mgoralLaboratoire Riva Inc2008-03-17Not applicableCanada
Ramipril Capsulescapsule1.25 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ramipril Capsulescapsule2.5 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ramipril Capsulescapsule5.0 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ramipril Capsulescapsule10.0 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ramipril-10capsule10 mgoralSivem Pharmaceuticals Ulc2013-10-23Not applicableCanada
Ramipril-2.5capsule2.5 mgoralSivem Pharmaceuticals Ulc2013-10-23Not applicableCanada
Ramipril-5capsule5 mgoralSivem Pharmaceuticals Ulc2013-10-23Not applicableCanada
Ran-ramiprilcapsule15 mgoralRanbaxy Pharmaceuticals Canada Inc.2014-11-24Not applicableCanada
Ran-ramiprilcapsule5 mgoralRanbaxy Pharmaceuticals Canada Inc.2008-06-25Not applicableCanada
Ran-ramiprilcapsule2.5 mgoralRanbaxy Pharmaceuticals Canada Inc.2008-06-25Not applicableCanada
Ran-ramiprilcapsule10 mgoralRanbaxy Pharmaceuticals Canada Inc.2008-06-25Not applicableCanada
Ran-ramiprilcapsule1.25 mgoralRanbaxy Pharmaceuticals Canada Inc.2008-06-25Not applicableCanada
Ratio-ramiprilcapsule2.5 mgoralRatiopharm Inc Division Of Teva Canada Limited2006-12-132014-09-19Canada
Ratio-ramiprilcapsule5.0 mgoralRatiopharm Inc Division Of Teva Canada Limited2006-12-132014-09-19Canada
Ratio-ramiprilcapsule10.0 mgoralRatiopharm Inc Division Of Teva Canada Limited2006-12-132014-09-19Canada
Ratio-ramiprilcapsule15 mgoralRatiopharm Inc Division Of Teva Canada Limited2009-05-052014-09-19Canada
Ratio-ramiprilcapsule1.25 mgoralRatiopharm Inc Division Of Teva Canada Limited2006-12-132014-09-19Canada
Rbx-ramiprilcapsule10 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Rbx-ramiprilcapsule1.25 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Rbx-ramiprilcapsule2.5 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Rbx-ramiprilcapsule5 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Sandoz Ramipriltablet5 mgoralSandoz Canada Incorporated2007-07-05Not applicableCanada
Sandoz Ramipriltablet10 mgoralSandoz Canada Incorporated2007-07-05Not applicableCanada
Sandoz Ramipriltablet1.25 mgoralSandoz Canada Incorporated2007-07-05Not applicableCanada
Sandoz Ramipriltablet2.5 mgoralSandoz Canada Incorporated2007-07-05Not applicableCanada
Teva-ramiprilcapsule2.5 mgoralTeva Canada Limited2007-05-02Not applicableCanada
Teva-ramiprilcapsule5 mgoralTeva Canada Limited2007-05-02Not applicableCanada
Teva-ramiprilcapsule1.25 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Teva-ramiprilcapsule10 mgoralTeva Canada Limited2007-05-02Not applicableCanada
Teva-ramiprilcapsule15 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Van-ramiprilcapsule10 mgoralVanc Pharmaceuticals Inc2016-01-27Not applicableCanada
Van-ramiprilcapsule1.25 mgoralVanc Pharmaceuticals Inc2016-01-27Not applicableCanada
Van-ramiprilcapsule15 mgoralVanc Pharmaceuticals Inc2016-01-27Not applicableCanada
Van-ramiprilcapsule2.5 mgoralVanc Pharmaceuticals Inc2016-01-27Not applicableCanada
Van-ramiprilcapsule5 mgoralVanc Pharmaceuticals Inc2016-02-12Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-ramiprilcapsule10 mgoralApotex Inc2006-12-12Not applicableCanada
Apo-ramiprilcapsule1.25 mgoralApotex Inc2006-12-12Not applicableCanada
Apo-ramiprilcapsule15 mgoralApotex Inc2009-05-01Not applicableCanada
Apo-ramiprilcapsule2.5 mgoralApotex Inc2006-12-12Not applicableCanada
Apo-ramiprilcapsule5 mgoralApotex Inc2006-12-12Not applicableCanada
Ramiprilcapsule10 mg/1oralCamber Pharmaceuticals2011-01-01Not applicableUs
Ramiprilcapsule10 mg/1oralExelan Pharmaceuticals, Inc.2008-06-27Not applicableUs
Ramiprilcapsule1.25 mg/1oralPhysicians Total Care, Inc.2008-07-14Not applicableUs
Ramiprilcapsule10 mg/1oralLupin Pharmaceuticals, Inc.2008-06-10Not applicableUs
Ramiprilcapsule5 mg/1oralBlue Point Laboratories2014-01-01Not applicableUs
Ramiprilcapsule5 mg/1oralAurobindo Pharma Limited2011-06-08Not applicableUs
Ramiprilcapsule10 mg/1oralBlenheim Pharmacal, Inc.2014-01-13Not applicableUs
Ramiprilcapsule10 mg/1oralAccord Healthcare Inc.2014-07-01Not applicableUs
Ramiprilcapsule1.25 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-11-20Not applicableUs
Ramiprilcapsule5 mg/1oralUnit Dose Services2008-06-24Not applicableUs
Ramiprilcapsule2.5 mg/1oralAmerican Health Packaging2008-01-22Not applicableUs
Ramiprilcapsule2.5 mg/1oralGolden State Medical Supply, Inc.2008-06-18Not applicableUs
Ramiprilcapsule5 mg/1oralbryant ranch prepack2008-06-18Not applicableUs
Ramiprilcapsule1.25 mg/1oralRoxane Laboratories, Inc2008-06-18Not applicableUs
Ramiprilcapsule2.5 mg/1oralBlue Point Laboratories2014-01-01Not applicableUs
Ramiprilcapsule10 mg/1oralActavis Pharma, Inc.2007-12-26Not applicableUs
Ramiprilcapsule10 mg/1oralPd Rx Pharmaceuticals, Inc.2008-06-09Not applicableUs
Ramiprilcapsule10 mg/1oralDr. Reddy's Laboratories Limited2008-06-18Not applicableUs
Ramiprilcapsule5 mg/1oralProficient Rx LP2008-06-10Not applicableUs
Ramiprilcapsule2.5 mg/1oralApotex Corp.2008-06-20Not applicableUs
Ramiprilcapsule10 mg/1oralCadila Healthcare Limited2010-11-20Not applicableUs
Ramiprilcapsule2.5 mg/1oralTeva Pharmaceuticals USA Inc2008-06-24Not applicableUs
Ramiprilcapsule1.25 mg/1oralCamber Pharmaceuticals2011-01-01Not applicableUs
Ramiprilcapsule1.25 mg/1oralExelan Pharmaceuticals, Inc.2008-06-27Not applicableUs
Ramiprilcapsule5 mg/1oralPhysicians Total Care, Inc.2009-07-30Not applicableUs
Ramiprilcapsule1.25 mg/1oralLupin Pharmaceuticals, Inc.2008-06-10Not applicableUs
Ramiprilcapsule5 mg/1oralAidarex Pharmaceuticals LLC2011-06-08Not applicableUs
Ramiprilcapsule1.25 mg/1oralDr. Reddy's Laboratories Limited2008-06-18Not applicableUs
Ramiprilcapsule5 mg/1oralProficient Rx LP2007-12-26Not applicableUs
Ramiprilcapsule10 mg/1oralBlue Point Laboratories2014-01-01Not applicableUs
Ramiprilcapsule10 mg/1oralAurobindo Pharma Limited2011-06-08Not applicableUs
Ramiprilcapsule1.25 mg/1oralActavis Pharma, Inc.2007-12-26Not applicableUs
Ramiprilcapsule5 mg/1oralAtlantic Biologicals Corps2008-06-18Not applicableUs
Ramiprilcapsule2.5 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-11-20Not applicableUs
Ramiprilcapsule10 mg/1oralUnit Dose Services2008-06-242016-03-31Us
Ramiprilcapsule5 mg/1oralAmerican Health Packaging2008-01-22Not applicableUs
Ramiprilcapsule5 mg/1oralGolden State Medical Supply, Inc.2008-06-18Not applicableUs
Ramiprilcapsule1.25 mg/1oralCadila Healthcare Limited2010-11-20Not applicableUs
Ramiprilcapsule2.5 mg/1oralRoxane Laboratories, Inc2008-06-18Not applicableUs
Ramiprilcapsule2.5 mg/1oralCardinal Health2008-06-18Not applicableUs
Ramiprilcapsule10 mg/1oralProficient Rx LP2008-06-10Not applicableUs
Ramiprilcapsule5 mg/1oralBlue Point Laboratories2014-01-01Not applicableUs
Ramiprilcapsule1.25 mg/1oralAccord Healthcare Inc.2014-07-01Not applicableUs
Ramiprilcapsule2.5 mg/1oralPd Rx Pharmaceuticals, Inc.2008-06-10Not applicableUs
Ramiprilcapsule2.5 mg/1oralExelan Pharmaceuticals, Inc.2008-06-27Not applicableUs
Ramiprilcapsule10 mg/1oralPhysicians Total Care, Inc.2008-02-21Not applicableUs
Ramiprilcapsule2.5 mg/1oralLupin Pharmaceuticals, Inc.2008-06-10Not applicableUs
Ramiprilcapsule5 mg/1oralApotex Corp.2008-06-20Not applicableUs
Ramiprilcapsule1.25 mg/1oralAurobindo Pharma Limited2011-06-08Not applicableUs
Ramiprilcapsule5 mg/1oralTeva Pharmaceuticals USA Inc2008-06-242016-03-31Us
Ramiprilcapsule2.5 mg/1oralCamber Pharmaceuticals2011-01-01Not applicableUs
Ramiprilcapsule10 mg/1oralAidarex Pharmaceuticals LLC2011-06-08Not applicableUs
Ramiprilcapsule2.5 mg/1oralDr. Reddy's Laboratories Limited2008-06-18Not applicableUs
Ramiprilcapsule5 mg/1oralDIRECT RX2014-01-01Not applicableUs
Ramiprilcapsule1.25 mg/1oralBlue Point Laboratories2014-01-01Not applicableUs
Ramiprilcapsule2.5 mg/1oralActavis Pharma, Inc.2007-12-26Not applicableUs
Ramiprilcapsule5 mg/1oralRoxane Laboratories, Inc2008-06-18Not applicableUs
Ramiprilcapsule2.5 mg/1oralRebel Distributors Corp2007-12-26Not applicableUs
Ramiprilcapsule5 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-11-20Not applicableUs
Ramipriltablet5 mg/1oralNorthwind Pharmaceuticals2014-12-30Not applicableUs
Ramiprilcapsule10 mg/1oralAmerican Health Packaging2008-01-22Not applicableUs
Ramiprilcapsule10 mg/1oralGolden State Medical Supply, Inc.2008-06-18Not applicableUs
Ramiprilcapsule2.5 mg/1oralCadila Healthcare Limited2010-11-20Not applicableUs
Ramiprilcapsule10 mg/1oralMedsource Pharmaceuticals2008-06-18Not applicableUs
Ramiprilcapsule, gelatin coated10 mg/1oralDIRECT RX2016-01-13Not applicableUs
Ramiprilcapsule5 mg/1oralCardinal Health2008-06-18Not applicableUs
Ramiprilcapsule2.5 mg/1oralProficient Rx LP2008-06-10Not applicableUs
Ramiprilcapsule1.25 mg/1oralCarilion Materials Management2008-06-18Not applicableUs
Ramiprilcapsule2.5 mg/1oralAccord Healthcare Inc.2014-07-01Not applicableUs
Ramiprilcapsule5 mg/1oralCamber Pharmaceuticals2011-01-01Not applicableUs
Ramiprilcapsule5 mg/1oralExelan Pharmaceuticals, Inc.2008-06-27Not applicableUs
Ramiprilcapsule2.5 mg/1oralPhysicians Total Care, Inc.2008-02-13Not applicableUs
Ramiprilcapsule5 mg/1oralLupin Pharmaceuticals, Inc.2008-06-10Not applicableUs
Ramiprilcapsule10 mg/1oralApotex Corp.2008-06-20Not applicableUs
Ramiprilcapsule2.5 mg/1oralAurobindo Pharma Limited2011-06-08Not applicableUs
Ramiprilcapsule10 mg/1oralTeva Pharmaceuticals USA Inc2008-06-242016-03-31Us
Ramiprilcapsule5 mg/1oralActavis Pharma, Inc.2007-12-26Not applicableUs
Ramiprilcapsule10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2008-06-24Not applicableUs
Ramiprilcapsule5 mg/1oralDr. Reddy's Laboratories Limited2008-06-18Not applicableUs
Ramiprilcapsule10 mg/1oralDIRECT RX2015-01-01Not applicableUs
Ramiprilcapsule10 mg/1oralBlue Point Laboratories2014-01-01Not applicableUs
Ramiprilcapsule10 mg/1oralRoxane Laboratories, Inc2008-06-18Not applicableUs
Ramiprilcapsule10 mg/1oralRebel Distributors Corp2007-12-26Not applicableUs
Ramiprilcapsule10 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-11-20Not applicableUs
Ramiprilcapsule10 mg/301oralNorthwind Pharmaceuticals2014-05-07Not applicableUs
Ramiprilcapsule1.25 mg/1oralAmerican Health Packaging2008-06-09Not applicableUs
Ramiprilcapsule1.25 mg/1oralApotex Corp.2008-06-20Not applicableUs
Ramiprilcapsule5 mg/1oralCadila Healthcare Limited2010-11-20Not applicableUs
Ramiprilcapsule10 mg/1oralREMEDYREPACK INC.2011-08-22Not applicableUs
Ramiprilcapsule2.5 mg/1oralProficient Rx LP2015-02-12Not applicableUs
Ramiprilcapsule1.25 mg/1oralGolden State Medical Supply, Inc.2008-06-18Not applicableUs
Ramiprilcapsule10 mg/1oralbryant ranch prepack2009-05-05Not applicableUs
Ramiprilcapsule10 mg/1oralDispensing Solutions, Inc.2008-06-18Not applicableUs
Ramiprilcapsule5 mg/1oralAccord Healthcare Inc.2014-07-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AcovilSanofi-Aventis (Spain)
CaraselAlmirall (Spain)
CardaceSanofi-Aventis (Finland), Aventis (India), Aventis (Indonesia)
DelixAventis (Germany, Turkey),
HyprenAstraZeneca (Austria)
LostapresTemis (Argentina)
PramaceAstra (Ireland), AstraZeneca (Sweden)
QuarkPolifarma (Italy)
TriatecSanofi-Aventis (Brazil, Chili, Denmark, France, Greece, Indonesia, Italy,Norway, Portugal, Sweden, Switzerland)
TritaceSanofi-Aventis (Argentina, Australia, Austria, Belgium, Czech Republic, Hong Kong, Hungary, Ireland, Israel, Malaysia, Mexico, Netherlands, Poland, Singapor, Thailand, United Kingdom), Aventis (New Zealand, Philippines, South Africa)
VesdilAstraZeneca (Germany), Promed (Germany)
Brand mixtures
NameLabellerIngredients
Altace HctValeant Canada Lp Valeant Canada S.E.C.
Altace Plus Felodipine 2.5mg + 2.5mgSanofi Aventis Canada Inc
Altace Plus Felodipine 5mg + 5mgSanofi Aventis Canada Inc
Apo-ramipril/hctzApotex Inc
PMS-ramipril-hctzPharmascience Inc
Ramipril-hctzSanis Health Inc
Ran-ramipril HctzRanbaxy Pharmaceuticals Canada Inc.
Teva-ramipril/hctzTeva Canada Limited
SaltsNot Available
Categories
UNIIL35JN3I7SJ
CAS number87333-19-5
WeightAverage: 416.5106
Monoisotopic: 416.231122144
Chemical FormulaC23H32N2O5
InChI KeyInChIKey=HDACQVRGBOVJII-JBDAPHQKSA-N
InChI
InChI=1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1
IUPAC Name
(2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-octahydrocyclopenta[b]pyrrole-2-carboxylic acid
SMILES
[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[[email protected]](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentPeptides
Alternative Parents
Substituents
  • Alpha peptide
  • N-acyl-alpha amino acid or derivatives
  • N-acyl-alpha-amino acid
  • Alpha-amino acid ester
  • Alpha-amino acid amide
  • Phenylpropylamine
  • Alpha-amino acid or derivatives
  • N-substituted-alpha-amino acid
  • Pyrrolidine carboxylic acid or derivatives
  • Pyrrolidine carboxylic acid
  • N-acylpyrrolidine
  • Aralkylamine
  • Fatty acid ester
  • Fatty acyl
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Tertiary carboxylic acid amide
  • Pyrrolidine
  • Cyclic alcohol
  • Tertiary amine
  • Carboxylic acid ester
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Secondary aliphatic amine
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. To reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events. May be used to slow the progression of renal disease in individuals with hypertension, diabetes mellitus and microalubinuria or overt nephropathy.
PharmacodynamicsRamipril is an ACE inhibitor similar to benazepril, fosinopril and quinapril. It is an inactive prodrug that is converted to ramiprilat in the liver, the main site of activation, and kidneys. Ramiprilat confers blood pressure lowing effects by antagonizing the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may sustain the effects of ramiprilat by causing increased vasodilation and decreased blood pressure.
Mechanism of actionThere are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Ramiprilat, the principle active metabolite of ramipril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Ramipril also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors.
Related Articles
AbsorptionThe extent of absorption is at least 50-60%. Food decreases the rate of absorption from the GI tract without affecting the extent of absorption. The absolute bioavailabilities of ramipril and ramiprilat were 28% and 44%, respectively, when oral administration was compared to intravenous administration.
Volume of distributionNot Available
Protein bindingProtein binding of ramipril is about 73% and that of ramiprilat about 56%.
Metabolism

Hepatic metabolism accounts for 75% of total ramipril metabolism. 25% of hepatic metabolism produces the active metabolite ramiprilat via liver esterase enzymes. 100% of renal metabolism converts ramipril to ramiprilat. Other metabolites, diketopiperazine ester, the diketopiperazine acid, and the glucuronides of ramipril and ramiprilat, are inactive.

SubstrateEnzymesProduct
Ramipril
Not Available
Diketopiperazine acidDetails
Ramipril
Not Available
Diketopiperazine esterDetails
Ramipril
RamiprilatDetails
Route of eliminationNot Available
Half lifePlasma concentrations of ramiprilat decline in a triphasic manner. Initial rapid decline represents distribution into tissues and has a half life of 2-4 hours. The half life of the apparent elimination phase is 9-18 hours and that of the terminal elimination phase is > 50 hours. Two elimination phases occur as a result of ramiprilat's potent binding to ACE and slow dissociation from the enzyme. The half life of ramiprilat after multiple daily doses (MDDs) is dose-dependent, ranging from 13-17 hours with 5-10 mg MDDs to 27-36 hours for 2.5 mg MDDs.
ClearanceNot Available
ToxicitySymptoms of overdose may include excessive peripheral vasodilation (with marked hypotension and shock), bradycardia, electrolyte disturbances, and renal failure. The most likely adverse reactions are symptoms attributable to its blood-pressure lowing effect. May cause headache, dizziness, asthenia, chest pain, nausea, peripheral edema, somnolence, impotence, rash, arthritis, and dyspnea. LD50 = 10933 mg/kg (orally in mice).
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Ramipril Action PathwayDrug actionSMP00154
Ramipril Metabolism PathwayDrug metabolismSMP00597
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Angiotensin-converting enzyme
Gene symbol: ACE
UniProt: P12821
rs4344 Not AvailableA Allele, homozygoteMore rapid response to drug treatment17885551
Angiotensin-converting enzyme
Gene symbol: ACE
UniProt: P12821
rs4344 Not AvailableG Allele, homozygoteMore rapid response to drug treatment17885551
Angiotensin-converting enzyme 2
Gene symbol: ACE2
UniProt: Q9BYF1
rs4344 Not AvailableG > AThose with the AA or GG gentypes respond better to treatment17885551
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9159
Blood Brain Barrier-0.8726
Caco-2 permeable-0.8491
P-glycoprotein substrateSubstrate0.7263
P-glycoprotein inhibitor INon-inhibitor0.7002
P-glycoprotein inhibitor IIInhibitor0.6295
Renal organic cation transporterNon-inhibitor0.8869
CYP450 2C9 substrateNon-substrate0.8541
CYP450 2D6 substrateNon-substrate0.8969
CYP450 3A4 substrateNon-substrate0.5082
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9304
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5691
Ames testNon AMES toxic0.9108
CarcinogenicityNon-carcinogens0.9267
BiodegradationNot ready biodegradable0.8903
Rat acute toxicity1.6732 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.98
hERG inhibition (predictor II)Non-inhibitor0.7901
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • King pharmaceuticals inc
  • Actavis elizabeth llc
  • Apotex inc
  • Cipla ltd
  • Dr reddys laboratories ltd
  • Invagen pharmaceuticals inc
  • Lupin ltd
  • Ranbaxy laboratories ltd
  • Roxane laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa
  • Watson laboratories inc
  • Zydus pharmaceuticals usa inc
  • King Pharmaceuticals, Inc.
Packagers
Dosage forms
FormRouteStrength
Capsuleoral1.25 mg
Capsuleoral15 mg
Capsuleoral10.0 mg
Capsuleoral15.0 mg
Capsuleoral5.0 mg
Capsuleoral10 mg
Capsuleoral2.5 mg
Capsuleoral5 mg
Tabletoral
Capsuleoral1.25 mg/1
Capsuleoral10 mg/1
Capsuleoral10 mg/301
Capsuleoral2.5 mg/1
Capsuleoral5 mg/1
Capsule, gelatin coatedoral10 mg/1
Tabletoral5 mg/1
Tabletoral1.25 mg
Tabletoral10 mg
Tabletoral2.5 mg
Tabletoral5 mg
Prices
Unit descriptionCostUnit
Altace 10 mg capsule2.87USD capsule
Altace 2.5 mg capsule2.54USD capsule
Altace 5 mg capsule2.53USD capsule
Altace 10 mg tablet2.37USD tablet
Altace 1.25 mg capsule2.2USD capsule
Ramipril 10 mg capsule2.19USD capsule
Altace 5 mg tablet2.02USD tablet
Altace 2.5 mg tablet1.93USD tablet
Ramipril 5 mg capsule1.87USD capsule
Ramipril 2.5 mg capsule1.78USD capsule
Altace 1.25 mg tablet1.63USD tablet
Ramipril 1.25 mg capsule1.59USD capsule
Altace 10 mg Tablet1.14USD tablet
Altace 2.5 mg Tablet0.9USD tablet
Altace 5 mg Tablet0.9USD tablet
Altace 1.25 mg Tablet0.78USD tablet
Apo-Ramipril 10 mg Tablet0.64USD tablet
Co Ramipril 10 mg Tablet0.64USD tablet
Jamp-Ramipril 10 mg Tablet0.64USD tablet
Mylan-Ramipril 10 mg Tablet0.64USD tablet
Novo-Ramipril 10 mg Tablet0.64USD tablet
Pms-Ramipril 10 mg Tablet0.64USD tablet
Ramipril 10 mg Tablet0.64USD tablet
Ran-Ramipril 10 mg Tablet0.64USD tablet
Ratio-Ramipril 10 mg Tablet0.64USD tablet
Sandoz Ramipril 10 mg Tablet0.64USD tablet
Apo-Ramipril 2.5 mg Tablet0.5USD tablet
Apo-Ramipril 5 mg Tablet0.5USD tablet
Co Ramipril 2.5 mg Tablet0.5USD tablet
Co Ramipril 5 mg Tablet0.5USD tablet
Jamp-Ramipril 2.5 mg Tablet0.5USD tablet
Jamp-Ramipril 5 mg Tablet0.5USD tablet
Mylan-Ramipril 2.5 mg Tablet0.5USD tablet
Mylan-Ramipril 5 mg Tablet0.5USD tablet
Novo-Ramipril 2.5 mg Tablet0.5USD tablet
Novo-Ramipril 5 mg Tablet0.5USD tablet
Pms-Ramipril 2.5 mg Tablet0.5USD tablet
Pms-Ramipril 5 mg Tablet0.5USD tablet
Ramipril 2.5 mg Tablet0.5USD tablet
Ramipril 5 mg Tablet0.5USD tablet
Ran-Ramipril 2.5 mg Tablet0.5USD tablet
Ran-Ramipril 5 mg Tablet0.5USD tablet
Ratio-Ramipril 2.5 mg Tablet0.5USD tablet
Ratio-Ramipril 5 mg Tablet0.5USD tablet
Sandoz Ramipril 2.5 mg Tablet0.5USD tablet
Sandoz Ramipril 5 mg Tablet0.5USD tablet
Apo-Ramipril 1.25 mg Tablet0.44USD tablet
Co Ramipril 1.25 mg Tablet0.44USD tablet
Jamp-Ramipril 1.25 mg Tablet0.44USD tablet
Mylan-Ramipril 1.25 mg Tablet0.44USD tablet
Pms-Ramipril 1.25 mg Tablet0.44USD tablet
Ramipril 1.25 mg Tablet0.44USD tablet
Ran-Ramipril 1.25 mg Tablet0.44USD tablet
Ratio-Ramipril 1.25 mg Tablet0.44USD tablet
Sandoz Ramipril 1.25 mg Tablet0.44USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1338344 No1996-05-212013-05-21Canada
CA2382387 No2005-06-212020-08-25Canada
US5403856 No1995-04-042012-04-04Us
US7368469 No2000-08-302020-08-30Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point109 °CPhysProp
water solubility3.5mg/LNot Available
logP2.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.039 mg/mLALOGPS
logP0.92ALOGPS
logP1.47ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)3.75ChemAxon
pKa (Strongest Basic)5.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area95.94 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity111.19 m3·mol-1ChemAxon
Polarizability44.78 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Edward Wilson, Martin Beasley, “Stabilized ramipril compositions and methods of making.” U.S. Patent US20060134213, issued June 22, 2006.

US20060134213
General References
  1. Cacciapuoti F, Capasso A, Mirra G, De Nicola A, Minicucci F, Gentile S: Prevention of left ventricular hypertrophy by ACE-inhibitor, ramipril in comparison with calcium-channel antagonist, felodipine. Int J Cardiol. 1998 Jan 31;63(2):175-8. [PubMed:9510492 ]
  2. Kleinert S: HOPE for cardiovascular disease prevention with ACE-inhibitor ramipril. Heart Outcomes Prevention Evaluation. Lancet. 1999 Sep 4;354(9181):841. [PubMed:10485736 ]
External Links
ATC CodesC09BB05C09BB07C09BA05C10BX06C10BX04C09AA05
AHFS Codes
  • 24:32.04
PDB Entries
FDA labelNot Available
MSDSDownload (53.6 KB)
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Ramipril.
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Ramipril.
AcebutololRamipril may increase the hypotensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Ramipril is combined with Aceclofenac.
AcetazolamideThe risk or severity of adverse effects can be increased when Ramipril is combined with Acetazolamide.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Ramipril is combined with Acetylsalicylic acid.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Ramipril.
AdapaleneThe risk or severity of adverse effects can be increased when Ramipril is combined with Adapalene.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Ramipril.
AlfuzosinAlfuzosin may increase the hypotensive activities of Ramipril.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Ramipril.
AliskirenRamipril may increase the hypotensive activities of Aliskiren.
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Ramipril.
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Ramipril.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Ramipril.
AlprenololRamipril may increase the hypotensive activities of Alprenolol.
AmbrisentanRamipril may increase the hypotensive activities of Ambrisentan.
AmifostineRamipril may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Ramipril is combined with Amiloride.
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Ramipril.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Ramipril.
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Ramipril.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Ramipril.
AmlodipineRamipril may increase the hypotensive activities of Amlodipine.
AmobarbitalAmobarbital may increase the hypotensive activities of Ramipril.
Amyl NitriteThe risk or severity of adverse effects can be increased when Ramipril is combined with Amyl Nitrite.
AntipyrineThe risk or severity of adverse effects can be increased when Ramipril is combined with Antipyrine.
ApraclonidineThe risk or severity of adverse effects can be increased when Ramipril is combined with Apraclonidine.
ApremilastThe risk or severity of adverse effects can be increased when Ramipril is combined with Apremilast.
AprotininAprotinin may decrease the antihypertensive activities of Ramipril.
ArdeparinArdeparin may increase the hyperkalemic activities of Ramipril.
AripiprazoleAripiprazole may increase the hypotensive activities of Ramipril.
AtenololRamipril may increase the hypotensive activities of Atenolol.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Ramipril.
AtorvastatinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Ramipril.
AzapropazoneThe risk or severity of adverse effects can be increased when Ramipril is combined with Azapropazone.
AzathioprineRamipril may increase the myelosuppressive activities of Azathioprine.
AzelastineThe risk or severity of adverse effects can be increased when Ramipril is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Ramipril is combined with Azilsartan medoxomil.
BalsalazideThe risk or severity of adverse effects can be increased when Ramipril is combined with Balsalazide.
BarbitalBarbital may increase the hypotensive activities of Ramipril.
BemiparinBemiparin may increase the hyperkalemic activities of Ramipril.
BenazeprilRamipril may increase the hypotensive activities of Benazepril.
BendroflumethiazideRamipril may increase the hypotensive activities of Bendroflumethiazide.
BenmoxinBenmoxin may increase the hypotensive activities of Ramipril.
BenoxaprofenThe risk or severity of adverse effects can be increased when Ramipril is combined with Benoxaprofen.
BepridilRamipril may increase the hypotensive activities of Bepridil.
BetaxololRamipril may increase the hypotensive activities of Betaxolol.
BethanidineRamipril may increase the hypotensive activities of Bethanidine.
BimatoprostRamipril may increase the hypotensive activities of Bimatoprost.
BisoprololRamipril may increase the hypotensive activities of Bisoprolol.
BoceprevirThe serum concentration of Ramipril can be decreased when it is combined with Boceprevir.
BosentanRamipril may increase the hypotensive activities of Bosentan.
BretyliumRamipril may increase the hypotensive activities of Bretylium.
BrimonidineRamipril may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Ramipril.
BromfenacThe risk or severity of adverse effects can be increased when Ramipril is combined with Bromfenac.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Ramipril.
BumetanideThe risk or severity of adverse effects can be increased when Ramipril is combined with Bumetanide.
BupranololRamipril may increase the hypotensive activities of Bupranolol.
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Ramipril.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Ramipril.
CanagliflozinThe risk or severity of adverse effects can be increased when Ramipril is combined with Canagliflozin.
CandesartanRamipril may increase the hypotensive activities of Candesartan.
CandoxatrilRamipril may increase the hypotensive activities of Candoxatril.
CaptoprilRamipril may increase the hypotensive activities of Captopril.
CarbamazepineThe metabolism of Ramipril can be increased when combined with Carbamazepine.
CaroxazoneCaroxazone may increase the hypotensive activities of Ramipril.
CarprofenThe risk or severity of adverse effects can be increased when Ramipril is combined with Carprofen.
CarteololRamipril may increase the hypotensive activities of Carteolol.
CarvedilolRamipril may increase the hypotensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Ramipril is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Ramipril is combined with Celecoxib.
CeliprololRamipril may increase the hypotensive activities of Celiprolol.
CertoparinCertoparin may increase the hyperkalemic activities of Ramipril.
ChloroquineThe risk or severity of adverse effects can be increased when Ramipril is combined with Chloroquine.
ChlorothiazideRamipril may increase the hypotensive activities of Chlorothiazide.
ChlorthalidoneRamipril may increase the hypotensive activities of Chlorthalidone.
CilazaprilRamipril may increase the hypotensive activities of Cilazapril.
CiprofloxacinRamipril may increase the arrhythmogenic activities of Ciprofloxacin.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Ramipril.
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Ramipril.
ClevidipineThe risk or severity of adverse effects can be increased when Ramipril is combined with Clevidipine.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Ramipril.
ClonidineRamipril may increase the hypotensive activities of Clonidine.
ClonixinThe risk or severity of adverse effects can be increased when Ramipril is combined with Clonixin.
CryptenamineRamipril may increase the hypotensive activities of Cryptenamine.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ramipril.
CyclophosphamideThe risk or severity of adverse effects can be increased when Ramipril is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Ramipril.
CyclothiazideRamipril may increase the hypotensive activities of Cyclothiazide.
D-LimoneneThe risk or severity of adverse effects can be increased when Ramipril is combined with D-Limonene.
DalteparinDalteparin may increase the hyperkalemic activities of Ramipril.
DapagliflozinThe risk or severity of adverse effects can be increased when Ramipril is combined with Dapagliflozin.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Ramipril.
DebrisoquinRamipril may increase the hypotensive activities of Debrisoquin.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Ramipril.
DeserpidineRamipril may increase the hypotensive activities of Deserpidine.
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Ramipril.
DexmedetomidineThe risk or severity of adverse effects can be increased when Ramipril is combined with Dexmedetomidine.
DiazoxideDiazoxide may increase the hypotensive activities of Ramipril.
DiclofenacThe risk or severity of adverse effects can be increased when Ramipril is combined with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Ramipril is combined with Diclofenamide.
DiflunisalThe risk or severity of adverse effects can be increased when Ramipril is combined with Diflunisal.
DiflunisalDiflunisal may decrease the antihypertensive activities of Ramipril.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Ramipril.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Ramipril.
DiltiazemRamipril may increase the hypotensive activities of Diltiazem.
DinutuximabThe risk or severity of adverse effects can be increased when Ramipril is combined with Dinutuximab.
DipyridamoleThe risk or severity of adverse effects can be increased when Ramipril is combined with Dipyridamole.
DorzolamideRamipril may increase the hypotensive activities of Dorzolamide.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Ramipril.
DoxazosinRamipril may increase the hypotensive activities of Doxazosin.
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Ramipril.
DrospirenoneRamipril may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Ramipril is combined with Droxicam.
DuloxetineRamipril may increase the orthostatic hypotensive activities of Duloxetine.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Ramipril.
EfonidipineRamipril may increase the hypotensive activities of Efonidipine.
EmpagliflozinThe risk or severity of adverse effects can be increased when Ramipril is combined with Empagliflozin.
EnalaprilRamipril may increase the hypotensive activities of Enalapril.
EnalaprilatRamipril may increase the hypotensive activities of Enalaprilat.
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Ramipril.
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Ramipril.
EpirizoleThe risk or severity of adverse effects can be increased when Ramipril is combined with Epirizole.
EplerenoneEplerenone may increase the hyperkalemic activities of Ramipril.
EplerenoneThe risk or severity of adverse effects can be increased when Ramipril is combined with Eplerenone.
EpoprostenolRamipril may increase the hypotensive activities of Epoprostenol.
EprosartanRamipril may increase the hypotensive activities of Eprosartan.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ramipril.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Ramipril.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Ramipril.
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Ramipril.
EsmololThe risk or severity of adverse effects can be increased when Ramipril is combined with Esmolol.
Etacrynic acidThe risk or severity of adverse effects can be increased when Ramipril is combined with Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Ramipril is combined with Etanercept.
EtodolacThe risk or severity of adverse effects can be increased when Ramipril is combined with Etodolac.
EtofenamateThe risk or severity of adverse effects can be increased when Ramipril is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Ramipril is combined with Etoricoxib.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Ramipril.
Evening primrose oilThe risk or severity of adverse effects can be increased when Ramipril is combined with Evening primrose oil.
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Ramipril.
exisulindThe risk or severity of adverse effects can be increased when Ramipril is combined with exisulind.
FelodipineRamipril may increase the hypotensive activities of Felodipine.
FenbufenThe risk or severity of adverse effects can be increased when Ramipril is combined with Fenbufen.
FenoldopamRamipril may increase the hypotensive activities of Fenoldopam.
FenoprofenThe risk or severity of adverse effects can be increased when Ramipril is combined with Fenoprofen.
FloctafenineThe risk or severity of adverse effects can be increased when Ramipril is combined with Floctafenine.
FlunixinThe risk or severity of adverse effects can be increased when Ramipril is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Ramipril is combined with Flurbiprofen.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Ramipril.
FosinoprilRamipril may increase the hypotensive activities of Fosinopril.
FurazolidoneFurazolidone may increase the hypotensive activities of Ramipril.
FurosemideThe risk or severity of adverse effects can be increased when Ramipril is combined with Furosemide.
GarlicThe serum concentration of Ramipril can be decreased when it is combined with Garlic.
GuanabenzRamipril may increase the hypotensive activities of Guanabenz.
GuanadrelRamipril may increase the hypotensive activities of Guanadrel.
GuanethidineRamipril may increase the hypotensive activities of Guanethidine.
GuanfacineRamipril may increase the hypotensive activities of Guanfacine.
HeparinHeparin may increase the hyperkalemic activities of Ramipril.
HexamethoniumRamipril may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the hypotensive activities of Ramipril.
HMPL-004The risk or severity of adverse effects can be increased when Ramipril is combined with HMPL-004.
HydracarbazineHydracarbazine may increase the hypotensive activities of Ramipril.
HydralazineRamipril may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideRamipril may increase the hypotensive activities of Hydrochlorothiazide.
HydroflumethiazideRamipril may increase the hypotensive activities of Hydroflumethiazide.
IbuprofenThe risk or severity of adverse effects can be increased when Ramipril is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Ramipril is combined with Ibuproxam.
IcatibantIcatibant may decrease the antihypertensive activities of Ramipril.
IcatibantThe risk or severity of adverse effects can be increased when Ramipril is combined with Icatibant.
IloprostIloprost may increase the hypotensive activities of Ramipril.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Ramipril.
IndapamideRamipril may increase the hypotensive activities of Indapamide.
IndenololRamipril may increase the hypotensive activities of Indenolol.
IndomethacinThe risk or severity of adverse effects can be increased when Ramipril is combined with Indomethacin.
IndoprofenThe risk or severity of adverse effects can be increased when Ramipril is combined with Indoprofen.
IndoraminRamipril may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Ramipril.
IproniazidIproniazid may increase the hypotensive activities of Ramipril.
IrbesartanRamipril may increase the hypotensive activities of Irbesartan.
IronThe risk or severity of adverse effects can be increased when Ramipril is combined with Iron.
Iron DextranThe risk or severity of adverse effects can be increased when Ramipril is combined with Iron Dextran.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Ramipril.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Ramipril is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Ramipril is combined with Isosorbide Mononitrate.
IsoxicamThe risk or severity of adverse effects can be increased when Ramipril is combined with Isoxicam.
IsoxsuprineThe risk or severity of adverse effects can be increased when Ramipril is combined with Isoxsuprine.
IsradipineRamipril may increase the hypotensive activities of Isradipine.
KebuzoneThe risk or severity of adverse effects can be increased when Ramipril is combined with Kebuzone.
KetoprofenThe risk or severity of adverse effects can be increased when Ramipril is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Ramipril is combined with Ketorolac.
LabetalolRamipril may increase the hypotensive activities of Labetalol.
LacidipineRamipril may increase the hypotensive activities of Lacidipine.
Lanthanum carbonateThe serum concentration of Ramipril can be decreased when it is combined with Lanthanum carbonate.
LatanoprostRamipril may increase the hypotensive activities of Latanoprost.
LeflunomideThe risk or severity of adverse effects can be increased when Ramipril is combined with Leflunomide.
LercanidipineRamipril may increase the hypotensive activities of Lercanidipine.
LevobunololThe risk or severity of adverse effects can be increased when Ramipril is combined with Levobunolol.
LevodopaRamipril may increase the orthostatic hypotensive activities of Levodopa.
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Ramipril.
LisinoprilRamipril may increase the hypotensive activities of Lisinopril.
LithiumThe serum concentration of Lithium can be increased when it is combined with Ramipril.
LofexidineRamipril may increase the hypotensive activities of Lofexidine.
LornoxicamThe risk or severity of adverse effects can be increased when Ramipril is combined with Lornoxicam.
LosartanRamipril may increase the hypotensive activities of Losartan.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Ramipril.
LoxoprofenThe risk or severity of adverse effects can be increased when Ramipril is combined with Loxoprofen.
LumiracoxibThe risk or severity of adverse effects can be increased when Ramipril is combined with Lumiracoxib.
MacitentanRamipril may increase the hypotensive activities of Macitentan.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Ramipril is combined with Magnesium salicylate.
ManidipineRamipril may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Ramipril is combined with Mannitol.
MasoprocolThe risk or severity of adverse effects can be increased when Ramipril is combined with Masoprocol.
MebanazineMebanazine may increase the hypotensive activities of Ramipril.
MecamylamineRamipril may increase the hypotensive activities of Mecamylamine.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Ramipril is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Ramipril is combined with Mefenamic acid.
MeloxicamThe risk or severity of adverse effects can be increased when Ramipril is combined with Meloxicam.
MesalazineThe risk or severity of adverse effects can be increased when Ramipril is combined with Mesalazine.
MesalazineMesalazine may decrease the antihypertensive activities of Ramipril.
MetamizoleThe risk or severity of adverse effects can be increased when Ramipril is combined with Metamizole.
MethazolamideThe risk or severity of adverse effects can be increased when Ramipril is combined with Methazolamide.
MethohexitalMethohexital may increase the hypotensive activities of Ramipril.
MethyclothiazideMethyclothiazide may increase the hypotensive activities of Ramipril.
MethyclothiazideThe risk or severity of adverse effects can be increased when Ramipril is combined with Methyclothiazide.
MethyldopaRamipril may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Ramipril.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Ramipril.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Ramipril.
MetipranololRamipril may increase the hypotensive activities of Metipranolol.
MetolazoneRamipril may increase the hypotensive activities of Metolazone.
MetoprololRamipril may increase the hypotensive activities of Metoprolol.
MibefradilRamipril may increase the hypotensive activities of Mibefradil.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Ramipril.
MinaprineMinaprine may increase the hypotensive activities of Ramipril.
MinoxidilRamipril may increase the hypotensive activities of Minoxidil.
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Ramipril.
MoclobemideMoclobemide may increase the hypotensive activities of Ramipril.
MoexiprilRamipril may increase the hypotensive activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Ramipril.
MoxonidineRamipril may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Ramipril is combined with Mycophenolate mofetil.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Ramipril is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Ramipril is combined with Nabumetone.
NadololRamipril may increase the hypotensive activities of Nadolol.
NadroparinNadroparin may increase the hyperkalemic activities of Ramipril.
NaftifineThe risk or severity of adverse effects can be increased when Ramipril is combined with Naftifine.
NaproxenThe risk or severity of adverse effects can be increased when Ramipril is combined with Naproxen.
NCX 4016The risk or severity of adverse effects can be increased when Ramipril is combined with NCX 4016.
NebivololRamipril may increase the hypotensive activities of Nebivolol.
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Ramipril.
NepafenacThe risk or severity of adverse effects can be increased when Ramipril is combined with Nepafenac.
NesiritideThe risk or severity of adverse effects can be increased when Ramipril is combined with Nesiritide.
NialamideNialamide may increase the hypotensive activities of Ramipril.
NicardipineRamipril may increase the hypotensive activities of Nicardipine.
NicorandilNicorandil may increase the hypotensive activities of Ramipril.
NifedipineThe risk or severity of adverse effects can be increased when Ramipril is combined with Nifedipine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Ramipril is combined with Niflumic Acid.
NiguldipineRamipril may increase the hypotensive activities of Niguldipine.
NilvadipineRamipril may increase the hypotensive activities of Nilvadipine.
NimesulideThe risk or severity of adverse effects can be increased when Ramipril is combined with Nimesulide.
NimodipineRamipril may increase the hypotensive activities of Nimodipine.
NisoldipineRamipril may increase the hypotensive activities of Nisoldipine.
NitrendipineRamipril may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Ramipril is combined with Nitroglycerin.
NitroprussideRamipril may increase the hypotensive activities of Nitroprusside.
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Ramipril.
ObinutuzumabRamipril may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Ramipril.
OlmesartanRamipril may increase the hypotensive activities of Olmesartan.
OlopatadineThe risk or severity of adverse effects can be increased when Ramipril is combined with Olopatadine.
OlsalazineThe risk or severity of adverse effects can be increased when Ramipril is combined with Olsalazine.
OmapatrilatRamipril may increase the hypotensive activities of Omapatrilat.
OrgoteinThe risk or severity of adverse effects can be increased when Ramipril is combined with Orgotein.
OxaprozinThe risk or severity of adverse effects can be increased when Ramipril is combined with Oxaprozin.
OxprenololRamipril may increase the hypotensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Ramipril is combined with Oxyphenbutazone.
PapaverineThe risk or severity of adverse effects can be increased when Ramipril is combined with Papaverine.
ParecoxibThe risk or severity of adverse effects can be increased when Ramipril is combined with Parecoxib.
PargylineRamipril may increase the hypotensive activities of Pargyline.
ParnaparinParnaparin may increase the hyperkalemic activities of Ramipril.
PenbutololRamipril may increase the hypotensive activities of Penbutolol.
PentobarbitalPentobarbital may increase the hypotensive activities of Ramipril.
PentoliniumRamipril may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Ramipril.
PerindoprilRamipril may increase the hypotensive activities of Perindopril.
PethidineThe risk or severity of adverse effects can be increased when Ramipril is combined with Pethidine.
PhenelzinePhenelzine may increase the hypotensive activities of Ramipril.
PheniprazinePheniprazine may increase the hypotensive activities of Ramipril.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Ramipril.
PhenoxybenzamineRamipril may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Ramipril.
PhentolamineRamipril may increase the hypotensive activities of Phentolamine.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Ramipril is combined with Phenylbutazone.
PimecrolimusThe risk or severity of adverse effects can be increased when Ramipril is combined with Pimecrolimus.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Ramipril.
PinacidilRamipril may increase the hypotensive activities of Pinacidil.
PindololRamipril may increase the hypotensive activities of Pindolol.
PiretanidePiretanide may increase the hypotensive activities of Ramipril.
PirfenidoneThe risk or severity of adverse effects can be increased when Ramipril is combined with Pirfenidone.
PirlindolePirlindole may increase the hypotensive activities of Ramipril.
PiroxicamThe risk or severity of adverse effects can be increased when Ramipril is combined with Piroxicam.
PivhydrazinePivhydrazine may increase the hypotensive activities of Ramipril.
PolythiazideRamipril may increase the hypotensive activities of Polythiazide.
PrazosinRamipril may increase the hypotensive activities of Prazosin.
PregabalinThe risk or severity of adverse effects can be increased when Ramipril is combined with Pregabalin.
PrimidonePrimidone may increase the hypotensive activities of Ramipril.
PropacetamolThe risk or severity of adverse effects can be increased when Ramipril is combined with Propacetamol.
PropranololRamipril may increase the hypotensive activities of Propranolol.
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Ramipril.
PTC299The risk or severity of adverse effects can be increased when Ramipril is combined with PTC299.
QuetiapineThe risk or severity of adverse effects can be increased when Ramipril is combined with Quetiapine.
QuinaprilRamipril may increase the hypotensive activities of Quinapril.
QuinethazoneQuinethazone may increase the hypotensive activities of Ramipril.
QuinineQuinine may increase the hypotensive activities of Ramipril.
RasagilineRasagiline may increase the hypotensive activities of Ramipril.
RemikirenRamipril may increase the hypotensive activities of Remikiren.
RescinnamineRamipril may increase the hypotensive activities of Rescinnamine.
ReserpineRamipril may increase the hypotensive activities of Reserpine.
ResveratrolThe risk or severity of adverse effects can be increased when Ramipril is combined with Resveratrol.
ReviparinReviparin may increase the hyperkalemic activities of Ramipril.
RiociguatRamipril may increase the hypotensive activities of Riociguat.
RisperidoneRamipril may increase the hypotensive activities of Risperidone.
RituximabRamipril may increase the hypotensive activities of Rituximab.
RofecoxibThe risk or severity of adverse effects can be increased when Ramipril is combined with Rofecoxib.
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Ramipril.
SacubitrilThe risk or severity of adverse effects can be increased when Ramipril is combined with Sacubitril.
SafrazineSafrazine may increase the hypotensive activities of Ramipril.
SalicylamideThe risk or severity of adverse effects can be increased when Ramipril is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Ramipril is combined with Salicylic acid.
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Ramipril.
SalsalateThe risk or severity of adverse effects can be increased when Ramipril is combined with Salsalate.
SaprisartanRamipril may increase the hypotensive activities of Saprisartan.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Ramipril.
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Ramipril.
SecobarbitalSecobarbital may increase the hypotensive activities of Ramipril.
SelegilineSelegiline may increase the hypotensive activities of Ramipril.
SelexipagRamipril may increase the hypotensive activities of Selexipag.
SeratrodastThe risk or severity of adverse effects can be increased when Ramipril is combined with Seratrodast.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Ramipril.
SildenafilSildenafil may increase the antihypertensive activities of Ramipril.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Ramipril.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Ramipril.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Ramipril.
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Ramipril.
SitaxentanRamipril may increase the hypotensive activities of Sitaxentan.
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Ramipril is combined with Sodium aurothiomalate.
SotalolThe risk or severity of adverse effects can be increased when Ramipril is combined with Sotalol.
SpiraprilRamipril may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Ramipril is combined with Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Ramipril is combined with SRT501.
St. John's WortThe metabolism of Ramipril can be increased when combined with St. John's Wort.
SulfasalazineThe risk or severity of adverse effects can be increased when Ramipril is combined with Sulfasalazine.
SulindacThe risk or severity of adverse effects can be increased when Ramipril is combined with Sulindac.
SuprofenThe risk or severity of adverse effects can be increased when Ramipril is combined with Suprofen.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Ramipril.
TadalafilTadalafil may increase the antihypertensive activities of Ramipril.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Ramipril.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Ramipril.
TelmisartanRamipril may increase the hypotensive activities of Telmisartan.
TemocaprilRamipril may increase the hypotensive activities of Temocapril.
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Ramipril.
TenoxicamThe risk or severity of adverse effects can be increased when Ramipril is combined with Tenoxicam.
TepoxalinThe risk or severity of adverse effects can be increased when Ramipril is combined with Tepoxalin.
TerazosinThe risk or severity of adverse effects can be increased when Ramipril is combined with Terazosin.
TeriflunomideThe risk or severity of adverse effects can be increased when Ramipril is combined with Teriflunomide.
TerlipressinRamipril may increase the hypotensive activities of Terlipressin.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Ramipril.
ThiamylalThiamylal may increase the hypotensive activities of Ramipril.
ThiopentalThiopental may increase the hypotensive activities of Ramipril.
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Ramipril.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Ramipril is combined with Tiaprofenic acid.
TiboloneRamipril may increase the hypotensive activities of Tibolone.
TicrynafenRamipril may increase the hypotensive activities of Ticrynafen.
TimololRamipril may increase the hypotensive activities of Timolol.
TinzaparinTinzaparin may increase the hyperkalemic activities of Ramipril.
TipranavirThe serum concentration of Ramipril can be decreased when it is combined with Tipranavir.
TizanidineTizanidine may increase the hypotensive activities of Ramipril.
TizanidineThe risk or severity of adverse effects can be increased when Ramipril is combined with Tizanidine.
TolazolineRamipril may increase the hypotensive activities of Tolazoline.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Ramipril is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Ramipril is combined with Tolmetin.
ToloxatoneToloxatone may increase the hypotensive activities of Ramipril.
TolvaptanTolvaptan may increase the hyperkalemic activities of Ramipril.
TorasemideRamipril may increase the hypotensive activities of Torasemide.
TrandolaprilRamipril may increase the hypotensive activities of Trandolapril.
TranilastThe risk or severity of adverse effects can be increased when Ramipril is combined with Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Ramipril.
TranylcypromineTranylcypromine may increase the hypotensive activities of Ramipril.
TravoprostRamipril may increase the hypotensive activities of Travoprost.
TreprostinilRamipril may increase the hypotensive activities of Treprostinil.
TriamtereneThe risk or severity of adverse effects can be increased when Ramipril is combined with Triamterene.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Ramipril.
TrichlormethiazideRamipril may increase the hypotensive activities of Trichlormethiazide.
TrimazosinRamipril may increase the hypotensive activities of Trimazosin.
TrimethaphanRamipril may increase the hypotensive activities of Trimethaphan.
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Ramipril.
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Ramipril.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Ramipril is combined with Trisalicylate-choline.
UdenafilUdenafil may increase the antihypertensive activities of Ramipril.
UnoprostoneRamipril may increase the hypotensive activities of Unoprostone.
ValdecoxibThe risk or severity of adverse effects can be increased when Ramipril is combined with Valdecoxib.
ValsartanValsartan may increase the hypotensive activities of Ramipril.
VardenafilVardenafil may increase the antihypertensive activities of Ramipril.
VerapamilThe risk or severity of adverse effects can be increased when Ramipril is combined with Verapamil.
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Ramipril.
XylometazolineRamipril may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Ramipril.
ZaltoprofenThe risk or severity of adverse effects can be increased when Ramipril is combined with Zaltoprofen.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Ramipril.
ZileutonThe risk or severity of adverse effects can be increased when Ramipril is combined with Zileuton.
ZomepiracThe risk or severity of adverse effects can be increased when Ramipril is combined with Zomepirac.
Food Interactions
  • Alcohol may increase the vasodilatory effects of ramipril.
  • Herbs that may attenuate the antihypertensive effect of ramipril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of ramipril.
  • Ramipril decreases the excretion of potassium. Salt substitutes containing potassium increase the risk of hyperkalemia.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.
Gene Name:
ACE
Uniprot ID:
P12821
Molecular Weight:
149713.675 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Levitt DG, Schoemaker RC: Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat. BMC Clin Pharmacol. 2006 Jan 6;6:1. [PubMed:16398929 ]
  3. Piepho RW: Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm. 2000 Oct 1;57 Suppl 1:S3-7. [PubMed:11030016 ]
  4. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Shah GB, Sharma S, Mehta AA, Goyal RK: Oculohypotensive effect of angiotensin-converting enzyme inhibitors in acute and chronic models of glaucoma. J Cardiovasc Pharmacol. 2000 Aug;36(2):169-75. [PubMed:10942157 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Peptide:proton symporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name:
SLC15A2
Uniprot ID:
Q16348
Molecular Weight:
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 24, 2016 02:15